Search

Search Constraints

You searched for: Author/Creator Collins, Steven

Search Results

2. A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?. (January 2020)

4. [F1–02–01]: DIAGNOSTIC AND PROGNOSTIC POWER OF FLUID AND NEUROIMAGING MARKERS OF PATHOLOGY AND NEURODEGENERATION: THE ALZHEIMER'S IMAGING, BIOMARKERS, AND LIFESTYLE (AIBL) STUDY OF AGEING EXPERIENCE. (1st July 2017)

5. [O1–06–04]: CSF P‐TAU IS CORRELATED WITH TAU PET, WHILE Aβ PET CORRELATES WITH Aβ1–42 AND THE T‐TAU/Aβ1–42 RATIO. (1st July 2017)

6. CSF biomarker variability in the Alzheimer's Association quality control program. Issue 3 (1st May 2013)

7. [P1–416]: CSF TOTAL TAU AS A BIOMARKER FOR NEURONAL INJURY IN ALZHEIMER's DISEASE: ALIGNING RATES OF CSF CHANGE WITH RATES OF HIPPOCAMPAL AND CORTICAL GRAY MATTER ATROPHY. (1st July 2017)

8. Cerebrospinal fluid neurofilament light chain is elevated in Niemann–Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response. (June 2020)

10. O4‐11‐05: The correlation between ß‐amyloid PET‐imaging and cerebrospinal fluid biomarkers is affected by the assay design. (1st July 2015)